IX Biopharma : Sustainability Report

Sustainability

Report

2022

16 September 2022

About this Report

GRI 102-1|102-46 | 102-50 | 102-52 | 102-53 | 102-54

iX Biopharma Ltd. (the Company or iX Biopharma) is proud to present our annual Sustainability Report for the Financial Year 2022. We have prepared the report with reference to the Global Reporting Initiative Standards (GRI Standards). The GRI Standards were chosen as they are the first global standards for sustainability reporting. The GRI Content Index on pages 13and 14 indicates the full list of GRI references and disclosures used in this report.

The report is also aligned to the SGX Sustainability Reporting Guide set out in Practice Note 7F of the Singapore Exchange Securities Trading Limited (SGX-ST) Listing Manual Section B: Rules of Catalist.

The report captures our environmental, social and governance performance from July 2021 to June 2022 (FY2022) with historical performance data (FY2021) included for comparison, for all our entities.

We are fully committed to sharing our sustainability journey with all our stakeholders. Please address any feedback you might have on our sustainability performance and any aspect of our sustainability report to:

Chew Sien Lup	Eva Tan
Chief Financial Officer	Chief Commercial Officer
[e-mail]	[e-mail]

Contents

About this Report	1
Sustainability Board Statement	2
About iX Biopharma	3
Sustainability at iX Biopharma	4
Stakeholder Engagement	5
Material ESG Factors and Targets	6
Economic
▪ Economic Performance	7
Environment
▪ Energy	7
Social
▪ Customer Health and Safety	8
▪ Training and Workplace Diversity	9
▪ Safety, Health and Environment	9
Innovation	10
Performance Metrics	12
GRI Content Index	13

Sponsor Statement

This Sustainability Report has been prepared by the company and its contents have been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the Sponsor), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist. This Sustainability Report has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this Sustainability Report, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this Sustainability Report. The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 8 Anthony Road, #01- 01, Singapore 229957, telephone: [phone].

1

Sustainability Board Statement

GRI 102-14

iX Biopharma is pleased to publish this FY2022 Sustainability Report together with our Annual Report for FY2022. It was prepared with reference to the Global Reporting Initiative's Sustainability Reporting Standards and captures our initiatives to integrate sustainability across our organisation in the areas of environment, social and governance (ESG).

Sustainability is integral for our business to achieve lasting commercial success. We have embarked on this sustainability journey by looking at our responsibility for the environment we are operating in, people in our workforce and innovative products for the healthcare industry.

In this endeavour, the Board provides guidance on the social, ethical and environmental impact of the Group's activities and oversees the monitoring and management of material sustainability issues and their performance indicators. We consider sustainability issues relating to the environment and social factors as part of the Group's strategic plans. The Management under the guidance of the Board is committed to integrating best sustainability practices into the Group's working environment and business operation.

Manufacturing may contribute to climate change through high energy and resource use, infrastructure development and complex supply chains, with potential to impact global climates. In this report, we estimate and report our Scope 2 emissions1 arising from our operations. From the next financial year, as we further scale up our operations, we will conduct a risk assessment in line with the Task Force on Climate-related Financial Disclosures (TCFD) framework with multiple climate scenarios to have a better understanding of our energy use and our Scope 1 and 2 emissions. This will serve as a foundation for us to establish new targets and recalibrate our existing targets. We will also be preparing for new sustainability reporting under the new listing requirements issued by the SGX, which will focus on climate reporting in line with the TCFD framework beginning in FY2023.

Environment

Innovation

People

Product

Governance

We are fully committed to our

We value our employees as the key pillar

Innovation is the cornerstone of the

As a pharmaceutical company, we

Corporate governance is at the centre of

environmental initiatives along our

for our long-term success. As an equal

Group and continues to be an important

comply with all relevant and material

our business in achieving our

entire value chain, from product

opportunity employer, we aspire to be

driver of future growth.

regulations and applicable industrial

sustainability goals. We uphold the

development to supply of goods. We

the workplace of choice for our staff. We

We are proud to report that 19 products

standards. All our products are

belief that good corporate governance

have identified energy as one of the

strongly believe in diversity and being

continuously assessed for health and

practices are essential in building a

have been registered or listed on the

material topics and will continue to

inclusive with regard to hiring policies.

safety impacts across our value chain.

sound corporation with an ethical

Australian Register of Therapeutic Goods

identify other areas of improvement

We employ the best talent, without

We have incorporated procedures

environment, thereby protecting the

(ARTG) as at end of FY2022.

where we can mitigate our

discrimination on race, gender or age.

throughout the manufacturing process

interests of all stakeholders. We strive to

We have developed an extensive

environmental impact.

We also value the importance of

from raw materials sourcing to rigorous

put in place a robust governance

pharmaceutical product pipeline utilising

product testing. We have also invested

framework to maintain integrity,

competency and proficiency in our

our patented WaferiX sublingual

in the implementation of a

transparency, accountability and

workforce to ensure the long-term

delivery technology.

pharmacovigilance monitoring system to

discipline in all our practices.

success of our business. During FY2022,

handle feedback and recall events.

we continued to invest in the training

and development of our employees to

enhance their skills and capabilities.

1 Scope 1 emissions are direct emissions from company-owned and controlled resources. In other words, emissions are released into the atmosphere as a direct result of a set of activities, at a company level. Scope 2 emissions are indirect emissions from the generation of purchased energy, from a utility provider.

2

About iX Biopharma

GRI 102-2|102-3|102-4|102-5|102-6|102-7|102-8

iX Biopharma Ltd (iX Biopharma or the Company, and together with its subsidiaries, the Group) is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent- protected formulations for sublingual delivery.

iX Biopharma has developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually for better absorption, faster onset of action and predictable effect. The WaferiX delivery platform is particularly useful for drug repurposing. Drug repurposing is where existing approved drugs are developed into new drugs targeting different indications or a different route of administration, at a lower development cost and risk.

iX Biopharma's pipeline of products under development includes dexmedetomidine wafer for the treatment of dementia related agitation and other indications. iX Biopharma's drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia and Singapore. iX Biopharma has developed Xativa, the world's first freeze-dried sublingual medicinal cannabis wafer.

The Group's nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products in Australia through more than 250 pharmacies and health food shops, in China through its flagship stores on Tmall Global and JD Worldwide, and globally through its online store.

Our manufacturing facility in Australia is licensed by the Therapeutic Goods Administration of Australia, complies with Good Manufacturing Practice, and supplies therapeutic products to hospitals and registered pharmacies.

iX Biopharma: Fast Facts

(as at 30 June 2022)

Indicator	Total				Breakdown
			Australia			Singapore		China
	Employees by region
		24		17		2
		43
		Male			Female
	Full Employees by gender
		26					17
	Total number of operations		4 (Corporate, R&D, trading, manufacturing)
	Net revenue			S$ 14.39 million
		Total Equity					Total liabilities
	Total capitalisation
		S$ 19.74 million					S$ 8.77 million

Figure 1

iX Syrinx,

Croydon,

Australia

3

Sustainability at iX Biopharma

GRI 102-11|102-18

Sustainability is integral to iX Biopharma's business to achieve the lasting commercial success of iX Biopharma. We have embarked on the sustainability journey by looking at our responsibility for the environment we are operating in, people in our workforce and innovative products for the healthcare industry. At iX Biopharma, we understand the importance of reducing our environmental impact and are committed to conducting business in a responsible manner by supporting the precautionary principle.

Sustainability Governance

GRI 102-18

Corporate governance is at the heart of our efforts in achieving our sustainability goals. We uphold the belief that good corporate governance practices are essential in building a sound corporation with an ethical environment, thereby protecting the interests of all stakeholders. We strive to put in place a robust governance framework to maintain the integrity, transparency, accountability and discipline in all our practices.

The Board provides guidance on the social, ethical and environmental impact of the Group's activities and oversees the

monitoring and management of material sustainability issues and their performance indicators. We consider sustainability issues relating to the environment and social factors as part of the Group's strategic plans. The Management under the guidance of the Board is committed to integrating best sustainability practices into the Group's working environment and business operation.

Supply chain

GRI 102-9|102-10

As we are accountable to our stakeholders, we endeavour to ensure that appropriate risk management, key internal controls and procedures are in place during the procurement of goods and

services.

As at end of FY2022, we have a pool of approximately 320 active suppliers, including contractors, clinical research organisations, professional consultants, and financial institutions which are mainly based in Singapore, Australia, China and USA.

We have adopted a 2- and 4-year qualification and review cycles for our suppliers of active ingredients and packaging materials. In the future, we aim to embed sustainability measures into our value chain and integrate environmental factors wherever possible and appropriate.

Figure 2 Automated sealing, packaging and inspection line

4